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Abstract: Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced
stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1
checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on
platinum-refractory recurrent/metastatic (R/M) HNSCC. Furthermore, checkpoint inhibitors are better
tolerated than chemotherapy. The state of the art in the treatment of R/M HNSCC is changing, thanks
to improved results for checkpoint inhibitors. Results for these treatments are also awaited in curative
settings and for locally advanced HNSCC. Unfortunately, the response rate of immunotherapy is low.
Therefore, the identification of predictive biomarkers of response and resistance to anti-PD1/PD-L1 is a
key point for better selecting patients that would benefit the most from immunotherapy. Furthermore,
the combination of checkpoint inhibitors with various agents is being currently evaluated to improve
the response rate, prolong response duration, and even increase the chances for a cure. In this review,
we summarize the most important results regarding immune targeting agents for HNSCC, predictive
biomarkers for resistance to immune therapies, and future perspectives.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC), including cancer of the oral cavity, pharynx,
and larynx, are a pervasive cancer with approximately 700,000 new cases and 350,000 cancer-related
deaths globally every year [1]. The risk factors most frequently associated with HNSCC are tobacco
use, alcohol consumption, and human papillomavirus (HPV) infection. HPV-positive HNSCC typically
arises in the oropharynx in younger men who are nonusers of tobacco and alcohol. This subtype of
HNSCC is characterized by a distinct biology and a better prognosis than HPV-negative HNSCC [2].
Most HNSCC patients are diagnosed with locally advanced disease comprising Stages III and IV
according to World Health Organization (WHO) classification. Despite advances in multimodality
treatments involving surgery, radiotherapy, chemotherapy, and/or targeted systemic treatment,
prognosis remains poor. More than 50% of patients with a locally advanced disease relapse even though
they have been treated with curative intent [3]. Patients with recurrent or metastatic (R/M) HNSCC
have dismal prognosis, with a median overall survival (mOS) of less than one year. For patients that
are not candidates for chemotherapy or have a progressive disease after platinum-based chemotherapy,
prognosis is even worse, with a one-year survival rate of less than 5% [4].
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Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor
(EGFR) [5] was first approved for second-line treatment based on a phase II trial [6]. Following the
publication of the pivotal EXTREME trial [5], cetuximab for first-line treatment in combination with
platinum-based chemotherapy was also approved by the Food and Drug Administration (FDA). Since
then, and before immunotherapy, no new therapy for R/M HNSCC had shown benefits for the overall
survival (OS) of R/M HNSCC patients. After nearly a decade, the first results on immunotherapy in
the form of checkpoint inhibitors were able to show survival benefits [7–9]. Despite the rather low
response rates, these results were welcomed with great enthusiasm, especially since immunotherapy
can induce long-lasting responses.
In this review, we summarize the most important results of immune-targeting agents for HNSCC,
predictive biomarkers for resistance to immune therapies, and future perspectives.
2. Immune System and Cancer
Immune surveillance is crucial for preventing malignant transformation by allowing for the early
elimination of cancer cells by the host immune system: the immune system targets unique antigens
that are presented on the tumor-cell surface. As a result of this phenomenon, immunocompromised
patients show an increased risk of developing cancers as a consequence of immune escape mechanisms.
Both HPV-positive and -negative HNSCCs belong to cancer types with the highest infiltration
by immune cells: high median regulatory T-cell (Treg)/CD8+ T-cell ratio and high levels of CD56
natural killer (NK) cell infiltration correlate with better survival [10]. Cancer cells develop mechanisms,
evading the immune effects of T cells. Despite this high infiltration by T cells, several suppressive
mechanisms have been identified for HNSCC [11–13]:
— Alterations or deficiencies of tumor human leukocyte antigen (HLA) class 1 expression (for
example, induced by EGFR that is expressed in 80% of HNSCC cases) with the overexpression of
antigens causing T-cell tolerance.
— Increase in immunosuppressive cytokines (interleukine-10, interleukine-6, TGF
(tumor-growth-factor)-β).
— Aberrant activation of transcription factors signal transducers and activators of transcription 3
(STAT3) that is linked to interleukine-6 signaling.
— Downregulation of T cells through the activation of inhibitory T-cell receptors cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1).
Most recently, the tumor microenvironment (TME) has been of increased interest. as it was
demonstrated that tumorigenesis is a process that is not only governed by tumor cells. Indeed, the TME
includes tumor cells, stromal cells (like carcinoma-associated fibroblasts (CAFs)), tumor-associated
macrophage (TAM), endothelial cells, and inflammatory or immune cells, as well as extracellular matrix
and soluble factors (like growth factors, cytokines, chemokines, matrix proteins, and proteases) [14].
TME facilitates tumor growth, invasion, migration, and metastasis [15]. TME stromal cells are genetically
altered and differ from normal cells. In CAFs isolated from oral cancer, oncogenes and tumor-suppressor
genes are expressed at altered levels [16]. CAFs are a major source of tumor-stimulating substances, such
as growth factors, chemokines, cytokines, and proteases. It is assumed that reciprocal communication
between tumor cells and CAF promotes formation of the TME, favoring tumor growth and invasion [17].
TAMs upregulate the production of factors involved in tumorigenesis. In oral cancer, the high density
of TAM is associated with poor prognosis [18,19].
3. Checkpoint Inhibitors
3.1. ANTI-PD1/PD-L1 Monoclonal Antibody
PD-1 is a surface transmembrane glycoprotein that belongs to the CD28 receptor family and is
expressed on activated T cells (CD4 and CD8+ T cells), while programmed death ligand 1 (PD-L1)
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belongs to the B7 superfamily and is expressed constitutively at low levels ion antigen-presenting cells
(APCs), with increased expression on tumor cells [20,21]. The interaction between PD-1 and PD-L1
negatively regulates the physiological antitumor immune response by decreasing cytokine production
and inducing T lymphocyte anergy and apoptosis [11]. The physiological aim is to prevent T-cell
overstimulation and autoimmunity, but it leads to the inhibition of the antitumor immune response.
As a consequence, drugs binding PD-1 or PD-L1 are able to turn off the inhibitory signal driven by this
tumor, thus restoring antitumor immunity.
3.1.1. Nivolumab
Nivolumab is a fully human IgG4 anti-PD1 checkpoint inhibitor. This immunotherapeutic agent
was approved by the FDA on November 2016, and by the European Medicines Agency (EMA) on
April 2017 for the treatment of platinum-refractory R/M HNSCC, on the basis of phase III trial data,
showing an overall survival benefit for this patient population [8]. Indeed, in the pivotal CheckMate
141 phase III study, nivolumab (3 mg/kg every two weeks until disease progression, unacceptable
toxicity, or withdrawal of consent) demonstrated a survival benefit in patients with R/M HNSCC,
with tumor progression/recurrence within 6 months of platinum therapy vs. standard of care (SoC;
docetaxel, methotrexate, or cetuximab, according to investigator’s choice): mOS was 7.5 vs. 5.1 months,
respectively, p = 0.01; regardless of PD-L1 expression (>1% or <1%) and regardless of tumor HPV
status [8,22]. However, the median progression-free survival (mPFS) was 2 months for nivolumab and
2.3 months for SoC, and the overall response rate (ORR) was low: 13.3% for nivolumab and 5.8% for
standard of care [22].
Treatment beyond progression was allowed for the experimental arm in CheckMate 141. Among
62 patients who received at least one dose of nivolumab after progression, three patients had a >30%
reduction in target lesion size [23]. Nevertheless, treatment with nivolumab beyond formal progression
should be considered carefully and only performed in the case of clear clinical benefit in order to
avoid overtreatment with immunotherapy, potentially leading to missed opportunities for subsequent
therapeutic options [24]. In particular, treatment with nivolumab should be stopped in the case of
marked performance status declines due to rapid disease progression. Median OS was slightly worse
in patients previously treated with cetuximab than in cetuximab-naïve patients (6.9 vs. 8.1 months,
respectively) [25]. Nivolumab was well-tolerated; with fewer grade 3–4 adverse events (AEs) than
the SoC: 13.1% vs. 35.1%, respectively. The vast majority of grade 3–4 AEs occurred in the first
6 months of initiating treatment of nivolumab, and the most common acute toxicities of any grade
comprised fatigue (14%), nausea (9%), and skin rash (8%) [8,22]. The AEs were evaluated according to
the Common Terminology Criteria for Adverse Events, version 4.0 [26].
In CheckMate 141, nivolumab even demonstrated a benefit in terms of quality of life (QoL), which was
evaluated through three EORTC questionnaires (QoL Questionnaire Core 30 (QLQ-C30), EORTC Head and
Neck Cancer-Specific Module (QLQ-H and N35), and three-level European Quality of Life 5-Dimensional
questionnaire (EQ-5D)) at baseline, after 2 months and every six weeks thereafter. At baseline, QoL was
similar in both arms. While nivolumab stabilized symptoms and functions, patients in the standard
arm had clinically relevant deterioration. Therefore, nivolumab delayed the time to deterioration of
patient-reported QoL outcomes among patients with platinum-refractory R/M HNSCC that negatively
impacted QoL [27]. Moreover, nivolumab is currently being evaluated in a phase II trial as neoadjuvant
therapy in patients with previously untreated resectable oral cavity SCC (NCT03021993).
3.1.2. Pembrolizumab
Pembrolizumab, a humanized anti-PD1 mAb, was the first immunotherapeutic agent showing
signs of efficacy in HNSCC. In the phase IB KEYNOTE-012 trial, 60 patients with PD-L1 positive (>1%)
R/M HNSCC (38% were HPV-positive and 62% were HPV-negative) were treated with pembrolizumab
10 mg/kg intravenously every two weeks [28]. Treatment was well-tolerated, with 17% of patients
having grade 3–4 AEs. ORR was 18% (25% in HPV-positive patients and 14% in HPV-negative patients).
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In the KEYNOTE-040 phase III trial, patients with R/M HNSCC that progressed within 3–6 months
after platinum-containing multimodality therapy were randomized to receive either pembrolizumab
monotherapy (200 mg every three weeks) or SoC (docetaxel, methotrexate, or cetuximab, according to
the investigator’s choice). Moreover, the study enrolled patients with R/M disease progressing during
or after platinum-based first- or second-line therapy. Updated survival results were recently published:
pembrolizumab provided a 20% reduction in the risk of death over SoC in patients with R/M HNSCC.
Better than expected survival in the standard arm was observed, probably due to subsequent therapies
including anti-PD1 mAb (indeed, 13% of patients received subsequent immunotherapy) [9]. On the
basis of the KEYNOTE-012 trial data, the FDA approved pembrolizumab as second-line therapy in
August 2016, but this approval is currently under revaluation following the results of the KEYNOTE-040
confirmatory trial [29].
Subgroup analyses were performed in KEYNOTE-040. Better survival benefit was observed in
the subgroup of patients with a tumor proportion score (TPS) ≥ 50%, which reflects the proportion
of tumor cells expressing PD-L1. On that basis, the EMA approved pembrolizumab for treatment of
platinum-refractory PD-L1 TPS ≥ 50% R/M HNSCC.
Furthermore, quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-H and N35 and
EQ-5D) were performed. Similarly, to nivolumab in CheckMate 141, pembrolizumab stabilized
symptoms, whereas the investigator’s choice led to clinically meaningful deterioration [30].
In the phase III KEYNOTE-048 trial, pembrolizumab was evaluated as first-line treatment, either
as monotherapy or in combination with platinum plus 5-fluorouracil chemotherapy, compared with
first-line SoC treatment (EXTREME regimen with a combination of platinum and 5-fluorouracil
chemotherapy plus cetuximab). The first results of this study were presented at the ESMO congress
in October 2018. In the monotherapy arm, pembrolizumab demonstrated a clear survival benefit
in patients with PD-L1 combined positive score (CPS) ≥ 20 (mOS 14.9 vs. 10.7 months, HR = 0.61,
95% CI 0.45–0.83, p = 0.0007) and, to a lesser extent, in patients with PD-L1 CPS ≥ 1 (mOS 12.3 vs.
10.3 months, HR = 0.78, 95% CI 0.64–0.96, p = 0.0086). The CPS reflects the immunehistochemistry (IHC)
of the expressed PDL1 target protein in tumor cells, tumor-infiltrating lymphocytes, and macrophages
(assessed with the IHC 22C3 pharmDx assay from Agilent), and could have better predictive value
than PDL1 expression on tumor cells alone. However, pembrolizumab did not prolong PFS. ORR
was lower in the pembrolizumab arm compared to SoC: 23% vs. 36% for CPS ≥ 20, respectively, and
19% and 35% for a CPS ≥ 1. The safety profile was in favor of immunotherapy with a grade 3–5 AE
rate of 17% with pembrolizumab vs. 69% with SoC. In these interim analyses, the combination of
pembrolizumab plus chemotherapy was found to be noninferior and superior to SoC for OS (mOS
13.0 vs. 10.7 months, HR 0.77, 95% CI 0.63–0.93, p = 0.0034), and similarly for the ORR (36% in both
arms). The grade 3–5 drug-related AE rate was 71% with pembrolizumab plus chemotherapy and
69% with SoC. Surprisingly, pembrolizumab plus chemotherapy was described as not superior to SoC
in patients with a CPS ≥ 20% and ≥1% (numerical data for these comparisons are not available) [31].
A peer-reviewed publication of the final results is pending.
Phase II KEYNOTE-689 is currently ongoing in patients with previously untreated, resectable,
locally advanced (LA) HNSCC to evaluate the addition of pembrolizumab as neoadjuvant and
postoperative adjuvant therapy (in combination with adjuvant radiotherapy; NCT03765918).
3.1.3. Atezolizumab
Atezolizumab is an anti-PD-L1 mAb. It has been studied in a phase I trial that enrolled 32 patients
with R/M HNSCC (including four with nasopharyngeal cancer) [32]. More than half of the patients
were heavily pretreated, as they had received at least two prior lines of therapy. Results were in line
with those of nivolumab and pembrolizumab with an ORR of 22%, median duration of response of
7.4 months (range of 2.8–45.8 months), mPFS of 2.6 months, and mOS of 6 months. Response in this
early trial showed no association with HPV status or PD-L1 expression level.
Int. J. Mol. Sci. 2019, 20, 5399 5 of 17
A phase III study is currently ongoing with atezolizumab as adjuvant therapy after definitive
local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and
neck (NCT03452137) [33].
3.1.4. Durvalumab
Durvalumab is a humanized anti-PD-L1 IgG1 mAb. In the single-arm phase II HAWK study,
durvalumab has been evaluated as a monotherapy in the treatment of immunotherapy-naïve R/M
HNSCC with high PD-L1 protein expression (≥25% of tumor cells). The primary endpoint was the
response rate. Durvalumab demonstrated efficacy with an ORR of 16.2% (95% CI, 9.9–24.4%) in all
patients, 29.4% (95% CI, 15.1–47.5%) for HPV-positive, and 10.9% (95% CI, 4.5–21.3%) for HPV-negative
patients. The mOS was 7.1 months (95% CI, 4.9–9.9) and mPFS was 2.1 months (95% CI, 1.9–3.7).
Durvalumab was well-tolerated with 8.0% Grade 3–4 treatment-related AEs, and none led to death [34].
In an attempt to improve the efficacy of monotherapy in patients with low or absent PD-L1
expression, durvalumab was studied in combination with the anti-CTLA-4 mAb tremelimumab. In the
phase II CONDOR study, R/M HNSCC patients with low (<25% of tumor cells) or negative PD-L1
expression and whose disease progressed on or after a platinum-containing regimen, were randomized
to receive either durvalumab or tremelimumab, or the combination of both agents. Again, the primary
endpoint was response rate: ORR was 9.2% (95% CI, 3.46–9.02%) for durvalumab monotherapy,
1.6% (95% CI, 0.04–8.53%) for tremelimumab monotherapy, and 7.8% (95% CI, 3.8–13.8%) for the
combination. Treatments were well-tolerated: grade 3–4 treatment-related AEs occurred in 15% of
patients overall, and immune-related AEs occurred in 6% of patients in the combination arm. There
was no clear benefit of the addition of tremelimumab compared to single-agent durvalumab in patients
with low/negative PD-L1 expression [35].
Results of the phase III EAGLE study were recently presented at the annual meeting of the
American Society of Clinical Oncology (ASCO) in May 2019. It evaluated durvalumab monotherapy
or the combination with tremelimumab vs. SoC in patients with R/M HNSCC, showing disease
progression after platinum-based chemotherapy regardless of PD-L1 status. Durvalumab monotherapy
and the combination of durvalumab and tremelimumab failed to improve survival when compared
with SoC [36]. Like in KEYNOTE-040, the SoC arm outperformed what was usually observed for SoC
arms in previous studies. Safety and tolerability were consistent with previous studies.
Looking at rapid changes with the advent of different anti-PD1 and PD-L1 agents for HNSCC,
the ongoing phase III KESTREL study will be interesting. KESTREL (NCT02551159) is investigating
the combination of durvalumab and tremelimumab vs. standard of care (EXTREME regimen) in
previously untreated R/M HNSCC patients.
3.1.5. Avelumab
Avelumab is a fully human anti-PD-L1 IgG1 mAb selectively binds to PD-L1 and competitively
blocks its interaction with PD-1, resulting in the activation of T cells. In a phase IA trial including patients
with previously treated solid tumors (no HNSCC patients were included), avelumab demonstrated an
acceptable toxicity profile, and a dose of 10 mg/kg was chosen for further development [37].
No data have been published yet on avelumab as a monotherapy in R/M HNSCC patients.
In the field of HNSCC, there was a recent media release regarding the CONFRONT phase
I/II trial. It evaluated the safety profile of combining avelumab with daily metronomic doses of
cyclophosphamide and a single fraction of radiotherapy at 8 Gy in patients with relapsed metastatic
HNSCC. The aim of this approach was to reverse the immune evasion of the tumor through a
radiotherapy-induced self-vaccination effect [38].
3.2. Combination Immunotherapy
Despite all efforts undertaken so far regarding immune therapies for HNSCC, the percentage of
patients that respond to inhibitory checkpoint receptor blockade is still unsatisfactory. Furthermore,
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the understanding regarding which patients finally respond sufficiently and durably is lacking,
and more research is needed in the absence of reliable predictive biomarkers. One way of overcoming
resistance and immune escape is to tackle more checkpoints in parallel; another is to enhance antigen
presentation and, by doing so, ‘priming’ T cells with other different modalities. Therefore, ongoing
trials evaluate immunotherapy in combination with various other treatments (cytotoxic agents, other
immunotherapeutic agents, radiation therapy) in order to improve the response rate and prolong the
response duration, providing a potential chance for curation with the least possible toxicity. Table 1
summarizes immunotherapeutic agent studied in recurrent/metastatic (R/M) head and neck squamous
cell carcinoma (HNSCC).









mOS (Months) (95% CI) AEs G3–G5







P: 23.3% P: 3.4 P: 14.9
P: 17% SoC: 69%




HR = 0.61 (0.45–0.83), p < 0.01
CPS ≥ 1
P: 19.1% P: 3.2 P: 12.3












35.6% P + C: 4.9 P + C: 13.0 P + C: 71% SoC:




HR = 0.77 (0.63–0.93), p < 0.01




N: 13.3% N: 2.0 N: 7.5 N: 13.1% SoC:







(10.4–19.6) P: 2.1 (2.1–2.3) P: 8.4 (6.4–9.4)
P: 13% SoC: 36%SoC: 10.1%
(6.6–14.5)
SoC: 2.3
(2.1–2.8) SoC: 6.9 (5.9–8.0)
HR = 0.80 (0.65–0.98)
TPS ≥ 50 φ φ
P: 11.6 (8.3–19.5)
φSoC: 6.6 (4.8–9.2)
HR = 0.53 (0.35–0.81), p < 0.01







SoC: 17.3% HR = 0.88 (0.72–1.08), p = 0.2
Durvalumab +
Tremelimumab




D + T:6.5 (5.5–8.2)
D + T: 16.3%
SoC: 24.2%SoC: 17.3%
SoC: 8.3 (7.3–9.2)
HR = 1.04 (0.85–1.26), p = 0.76
Durvalumab PD-L1 II (HAWK) [34]
PD-L1 16.2%
(9.9–24.4)























2.0 (1.9–2.1) 5.5 (3.9–7.0) 15.8%
<25%
Atezolizumab PD-L1 I [32] All 22% 2.6 6.0
Durvalumab +




(13.4–43.1) φ φ 80%
Abbreviations: ORR: overall response rate; PFS: progression free survival; mOS: median overall survival; SoC:
standard of care; HR: hazard ratio; AEs: adverse events; CPS: numbers of PD-L1 positive cell (tumor cell, lymphocytes,
macrophages) divided by all viable tumor cells × 100; TPS: percentage of tumor cell with membranous PD-L1
expression divided by all viable tumor cells; φ: no data available. In italics are data presented at the American
Society of Clinical Oncology (ASCO) or ESMO Congress that have not yet been peer-reviewed.
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3.2.1. Combination with Other Checkpoint Inhibitors (mAb)
CTLA-4 Blockade
CTLA-4 is another inhibitory checkpoint implicated in T-cell downregulation. It is expressed
on the surface of activated cytotoxic T lymphocytes, binding to B7 ligands present on the surface of
APCs and suppressing activation following T-cell receptor (TCR) binding of the antigens presented by
major histocompatibility complex (MHC) proteins. The inhibitory signal of CTLA-4 competes with the
stimulatory CD28 receptor for binding to the B7 ligand [13].
The CTLA-4 and PD-1/PD-L1 pathways are considered to be nonredundant. The combination of
anti-CTLA4 and anti-PD1/PD-L1 has already demonstrated n a synergistic effect in the blocking of
these two checkpoint inhibitors in metastatic melanoma. This synergistic effect results from the fact
that PD-1 and CTLA-4 receptors downregulate T cells by distinct mechanisms [40].
Ipilimumab, an IgG1 anti-CTLA-4 mAb, was developed earlier than PD-1/L1-directed therapies.
PD-1/PD-L1 inhibitors were developed thereafter, with the intention of being more specific to have
fewer side effects than targeting the CTLA-4 pathway, and because PD-L1 expression is specifically
found on tumor cells [13].
As explained above, tremelimumab, another anti-CTLA-4 mAb, was evaluated in combination
with durvalumab in the phase II CONDOR study and in the phase III EAGLE study [35,36]. In both
studies, the addition of tremelimumab failed to improve ORR and outcome.
The combination of ipilimumab and nivolumab is also currently being evaluated in a phase
III study as first-line treatment vs. SoC (EXTREME regimen) in R/M HNSCC (CheckMate 651,
NCT02741570). Results of this study are due shortly. Furthermore, the combination of nivolumab and
ipilimumab is currently being evaluated in the phase I/II IMCISION trial as a neoadjuvant therapy in
patients with previously untreated resectable LA HNSCC (NCT03003637).
Lymphocyte Activation Gene 3 (LAG-3) Blockade
LAG-3 is expressed on the surface of activated CD4 and CD8+ T cells, as well as several subtypes
of NK and dendritic cells [41,42]. It recognizes MHC class II, and preferentially suppresses T cells
responsive to stable complexes of peptide and MHC class II.
An anti-LAG-3 mAb, relatlimab (BMS-986016), is evaluated in a phase I/IIA dose escalation and
expansion study, alone and in combination with nivolumab in advanced solid tumors, including an
HNSCC cohort (CA224-020 study, NCT01968109). Results are currently not available.
Other Targets
Other antibody drugs for solid tumors are being developed and could be tested in the treatment
of HNSCC in future. For example, antibodies against the T-cell immunoglobulin and mucin domain 3
(TIM-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and killer cell immunoglobulin-like
receptor (KIR).
3.2.2. Combination with Other Immune Modulators
Several chemical compound-based immune modulators have been developed and are in the early
stages of phase trials as assessed in combination with immunotherapy to improve outcomes.
STAT3 Inhibitor
STAT3 is a transcription factor that contributes to the immunosuppressive tumor microenvironment.
Preclinical studies have shown that STAT3 inhibition can increase radiosensitivity [43]. The combination
of durvalumab and either danvatirsen (AZD9150, a STAT3 inhibitor) or AZD5069 (a CXC chemokine
receptor 2 (CXCR2) inhibitor) was evaluated in a phase IB/II trial (SCORES study, NCT02499328).
Part A in this study investigated dose escalation in solid tumors with the STAT3 inhibitor (durvalumab
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alone or durvalumab in combination with danvatirsen) and the CXCR2 inhibitor (durvalumab alone or
in combination with AZD5069). Part B included a dose-expansion cohort for HNSCC, and tested the
combination of durvalumab with either danvatirsen (STAT3 inhibitor) or AZD5069 (CXCR2 inhibitor) in
PD-L1 pretreated/naïve patients, and as monotherapy with primary-endpoint ORR and disease-control
rate (DCR). Results from the dose escalation in solid tumor were reported at the 2017 ESMO Annual
Meeting and suggested that it enhanced antitumor activity with the combination of danvatirsen
and durvalumab [44]. Preliminary results of the dose-expansion cohort with 38 patients with PD-L1
treatment naïve/pretreated R/M HNSCC treated with the combination of durvalumab and danvatirsen
were presented at the 2018 ESMO Annual Meeting. The ORR was 26% with four complete responses
and six partial responses. Responses were observed regardless of HPV status or PD-L1 expression.
Safety and tolerability were confirmed with manageable and reversible AEs, the most important being
an increase of thrombocytopenia and liver enzymes [39].
These data suggest antitumor activity from combining an anti-PD-L1 and a STAT3 inhibitor, and
warrant further investigation.
CXCR2 Inhibitor
CXCR2 is a receptor for cytokines. It is overexpressed in HNSCC and is implicated in disease
proliferation via interleukine-8 signaling [11,45]. The CXCR2 inhibitor AZD5069 was evaluated in
combination with durvalumab in the early trial SCORES study as mentioned above. Preliminary results
of the dose expansion cohort with 20 patients with PD-L1 treatment naïve/pretreated R/M HNSCC
treated with the combination of durvalumab and AZD5069 were presented at the 2018 ESMO Annual
Meeting. Unfortunately, unlike results of the STAT3 inhibitor, the addition of AZD5069 did not seem to
improve outcome as the ORR was 10% and causally related AEs occurred in 76% of patients [39].
IDO1 Inhibitor
Indoleamine 2,3-dioxygenase 1 (IDO1) is a catabolizing enzyme that induces immune tolerance
by suppressing T cells through tryptophan depletion and kynurenine accumulation in the local tumor
microenvironment. It is associated with a poor outcome in laryngeal SCC [46]. Several IDO1 inhibitors
are in clinical development.
Epacadostat is a potent and highly selective oral inhibitor of the IDO1 enzyme. Results of the
phase I part from phase I/II trial ECHO-202/KEYNOTE-037 combining epacadostat and pembrolizumab
in patients with advanced solid tumors have recently been published, but among the 62 enrolled
patients, only two had R/M HNSCC [47]. Preliminary results of the HNSCC cohort of this phase I/II
trial were presented at the annual 2017 ASCO congress. Eligible patients had PD-1/PD-L1 naïve R/M
HNSCC that had received at least one line of platinum-based chemotherapy. Thirty-eight patients
were enrolled, two with R/M HNSCC. In patients that had received one or two lines of treatment,
ORR was 34% (2 CR and 8 PR) and ORR was 62% (eight stable diseases). In patients with at least three
prior lines of treatment, ORR and DCR were 14% (1 PR) and 43% (2 SD), respectively. Response was
observed regardless of HPV status. PFS and biomarker analyses have not been presented so far. The
combination was well-tolerated, with 11% of patients presenting grade ≥3 treatment-related AEs [48].
Navoximod is a small-molecule inhibitor of IDO1. It was evaluated in combination with
atezolizumab in a phase IB study on advanced solid tumors. A total of 158 patients were included in
this study, among which were six patients with HNSCC (three in the dose-escalation cohort and three
in the dose-expansion cohort). Specific HNSCC results are not available, though this combination was
considered safe. The RR was 9% in the dose-escalation cohort, and 11% in the expansion cohort. Hence,
although activity was observed, there was no clear evidence of any benefit from the combination of
navoximod with atezolizumab in treating unselected patients [49].
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3.2.3. Combination with Chemoradiotherapy
Despite multimodality treatments (including surgery followed by radiotherapy or
chemoradiotherapy (CRT), or definitive CRT) routinely used for locally advanced HNSCC, the risk of
recurrence is high, and prognosis remains dismal. The addition of immunotherapy to radiotherapy or
CRT is currently under investigation with the aim of increasing the response rate and reducing the risk
of recurrence.
Results of a safety study of pembrolizumab in combination with weekly cisplatin-based CRT
have been presented at the 2017 ASCO Annual Meeting. Twenty-seven patients with Stage III–IVB
HNSCC received pembrolizumab once prior to CRT, twice during CRT and, finally, five times after
CRT. CRT with weekly cisplatin was chosen because it is potentially less myelosuppressive and to
avoid the need for dexamethasone that may dampen immune response. All patients completed the
full radiation dose (70 Gy) without significant delay, 85% received at least 200 mg/m2 of cisplatin and
78% completed all planned doses of pembrolizumab. Hence, pembrolizumab in combination with
weekly cisplatin-based CRT was safe and did not impair CRT [50]. Interim analysis results of this
phase IB study were also presented at the 2018 Annual Meeting of the Society for Immunotherapy of
Cancer (SITC). In 34 patients with HPV-positive patients, the final complete response rate based on
imaging and surgical biopsy was 85%, and one-year PFS was estimated at 97.5%. Again, the addition
of pembrolizumab did not seem to impact the safety of standard chemoradiotherapy [51].
These are encouraging results; however, results from randomized trials are needed in order to
confirm whether the addition of immunotherapy increases CRT activity. Several phase III studies are
ongoing with different checkpoint inhibitors. The KEYNOTE-412 phase III trial with pembrolizumab
plus cisplatin-based CRT vs. CRT alone for locally advanced HNSCC is among them (NCT03040999).
The phase III JAVELIN Head and Neck 100 trial is currently evaluating the benefit of combining
avelumab treatment with the standard definitive chemoradiotherapy with cisplatin, followed by
maintenance of avelumab for one year (NCT02952586). In the ongoing phase III REACH trial, the
combination of avelumab, cetuximab, and radiation therapy is evaluated in comparison with CRT in
fit patients, and with cetuximab and radiation therapy in unfit patients (NCT02999087).
3.3. Oncolytic Virotherapy
In preclinical studies, oncolytic viruses have been found to reduce tumor burden and to
prime antitumor immunity as well as overcome resistance to checkpoint inhibitors by broadening
neo-antigenome-directed T-cell responses [11,52,53].
Talimogene laherparepvec (T-VEC) is a modified attenuated herpes simplex virus type 1 that
can induce antitumor response by replicating in tumor cells and producing granulocyte macrophage
colony-stimulating factor (GM-CSF). It has already been approved for treatment of metastatic melanoma
as a single agent [54]. T-VEC is currently evaluated in the treatment of R/M HNSCC in the ongoing phase
IB/III KEYNOTE-137 (NCT02626000). Preliminary results of 36 treated patients with platinum-refractory
R/M HNSCC and injectable disease were presented at the ASCO congress in 2018 with an ORR of
16.7% and a disease control rate of 38.9% [55].
Unfortunately, as the ORR was too similar to that of pembrolizumab monotherapy, phase III will
not be initiated.
4. Immune-Related Adverse Events
Immunotherapy with immune checkpoint inhibitors is better tolerated than chemotherapy.
Nevertheless, some patients develop immune-related AEs (irAEs) that can be serious or even fatal.
These irAEs are related to drug-induced immune dysregulation.
IrAEs can appear at every organ site, but usually comprise endocrinopathies (such as thyroid
insufficiency, acute hypophysitis, hypopituitarism, primary adrenal insufficiency, hypogonadism,
hypercalcemia, and diabetes mellitus) [56], gastrointestinal toxicity, liver toxicity and, less frequently,
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immune-related pneumonitis. In KEYNOTE-048, irAEs were reported separately as “events of interest”
affecting about one-quarter of pembrolizumab-treated patients, with 4% classified as grade 3–5. The
most common irAEs of any grade were hypothyroidism (15%), pneumonitis (4%), and infusion-related
reaction (3%) [8].
As presented at ASCO 2018, in a prospective study including 114 patients with metastatic HNSCC
(unselected for PD-L1 status) that received ant-PD1 therapy, the development of irAEs was associated
with superior ORR (30.6% vs. 12.3%), PFS, and OS (12.5 vs. 6.8 months, p = 0.003) [57].
5. Predictive Biomarkers
The special interest in identifying prognostics as well as predictive markers for treatment responses
arises because only a proportion of patients benefit from immune checkpoint inhibitor treatment.
Different predictive biomarkers are subject to research, but none of these markers have been validated
yet. This review focuses on a selection of potential predictive biomarkers that help to identify patients
who respond to immunotherapy in HNSCC.
5.1. PD-L1 Expression
The expression of PD-L1 is routinely assessed in HNSCC biopsies by IHC. Though PD-L1
overexpression has been associated with higher response rates and better outcomes in patients treated
with immune checkpoint inhibitor in different tumor types, cutoff values are not standardized, and
the response to treatment is observed in PD-L1 negative cancers [58]. Studies in lung-cancer tissue
suggest overexpression as defined as the percentage of viable tumor cells showing partial or complete
membrane staining as compared to all viable tumor cells (tumor proportion score or TPS) being
greater than 50% as a stronger predictive biomarker [59]; in HNSCC, different cutoff values for PD-L-1
overexpression have been used in clinical trials (Table 2).
Table 2. Difference in PD-L1 expression in clinical trials for HNSCC.
Immune Checkpoint








(+) (%) OS (Months)
Nivolumab PD-L1 CheckMate141 III TCs >1% 13.3% 17% 7.5










CPS >1 17.3% 8.4




CPS > 20 23.3% 13 (in comb. withchemotherapy)
TC: tumor cell.
Uncertainty arises from the different antibody kits used [60], but also from the examined tissue:
besides differences in PD-L1 expression in different types of cancer tissue, dynamic expression varying
in intensity depending on location, prior treatments, and inhomogeneous expression inside tumor
tissue [61], it has been suggested that PD-L-1 expression should be assessed in the immune and stromal
cells of the tumor microenvironment [59], as well as extratumoral sites such as lymph nodes, blood,
and bone marrow [62]. These considerations are taken into account in the CPS expressing PD-L1
positivity of cancer microenvironment as a ratio of the number of all PD-L1 positive cells (including
lymphocytes, macrophages, and tumor cells) divided by the total number of tumor cells [63].
5.2. HPV and Viral Neoantigen
HPV-positive and -negative HNSCC are pathogenetically different entities with different clinical
outcomes and prognoses. Persistent infection with HPV type 16 is an important risk factor for the
development of oropharyngeal squamous cell carcinoma, with better prognosis in term of OS when
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treated with standard chemotherapy [2]. These results correspond to IHC findings of HPV-positive
HNSCC showing increased infiltration of CD8+ lymphocytes with the presence of less Treg with
a potentially less immunosuppressive tumor microenvironment [64]. Even if treatment has yet
been not suited to HPV status, it is to be presumed that immune properties also differ between
these two patient groups [65]. Whether high PD-L1 expression on IHC for oropharyngeal cancers
is due to HPV-related tumors remains unclear [66]. The expression of checkpoints on tumor cells,
tumor-infiltrating lymphocytes, or macrophages can have major implications for immune therapies
and their efficacy for HNSCC [31].
Clinical trials investigated a treatment response to checkpoint inhibitors with regard to
HPV-positive and -negative HNSCC. While the KEYNOTE-012 evaluating pembrolizumab in HNSCC
reported an increased ORR in HPV-positive patients (32% vs. 14%) [28], neither the KEYNOTE-040
trial (pembrolizumab) [9] nor the CheckMate 141 trial (nivolumab) [8] could confirm these findings,
suggesting that HPV positivity is not a predictive marker for a response to checkpoint inhibitors
in HNSCC.
5.3. T-Cell-Inflamed Gene Expression Profile
Besides the expression of PD-L-1 in the TME, the composition of infiltrating immune cells (CD8+
T cells, Treg, NK cells, macrophages) seems to have an impact on treatment response to checkpoint
inhibitors [67]. The degree of infiltration of CD8+ T cells has been correlated with improved response
to anti-PD-1/PD-L1 agents in melanoma [68], results that could be observed for HNSCC in retrospective
studies, showing a correlation between treatment response and degree of infiltration with CD8+ T
cells, as well as with the ratio of CD8+T cells/Treg [69].
Studies of T-cell activity in cancer tissue have been developed using gene expression profiling (GEP),
a technique allowing to identify an “inflammatory T-cell phenotype” [70,71] as well as the “interferon-γ
gene expression signature” assay, identifying the expression of genes of T-cell activation [72]. In the
KEYNOTE-012 and KEYNOTE-055 trials, GEP was shown to be a predictive marker for checkpoint
inhibitor response with benefits in PFS and OS regardless of viral status [72].
5.4. Tumor Mutational Burden
Tumor mutational burden (TMB), a technique measuring the total number of mutations in
the tumor genome by whole-exome sequencing (WES), has been shown to be a predictive marker
of response to checkpoint inhibitors in different tumors [73]. Higher TMB was associated with
better outcomes, with special benefit in patients with high TMB when treated with combined
anti-CTLA4/anti-PD-1/PD-L1 as compared to monotherapy treatment (ORR 77% vs. 21%) [74].
In HNSCC, TMB was investigated in a retrospective study of 126 patients treated with
anti-PD-1/anti-PD-L1 therapy, showing higher TMB in responders compared to nonresponders
(median OS 17.7 vs. 7.1 months, p < 0.01) [75]; TMB was higher in smokers. Interestingly, patients with
HPV-negative cancers who responded to ICI had a greater OS of up to 20 months in the presence of
high TMB compared to 6 months in patients with low TMB [69].
6. Conclusions
The standard-of-care treatment for HNSCC is currently changing, thanks to the benefits
demonstrated by immunotherapy, such as anti-PD-1/PD-L1 checkpoint inhibitors. The latter became a
standard treatment for R/M HNSCC by improving OS and QoL and showing a favorable toxicity profile.
Responses to immunotherapy can be long-lasting, even in heavily pretreated patients. Nevertheless,
the response rate remains low, and combinations with other immunotherapeutic drugs and other
treatments are currently under evaluation. Furthermore, the identification of predictive biomarkers
in treatment with checkpoint inhibitors is crucial, and predictive biomarkers have been identified
in pivotal trials of pembrolizumab and nivolumab in HNSCC with PD-L1 expression in tumor
microenvironments, T-cell activity as assessed by GEP and IFN-γ gene expression signature, as well as
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TMB. A combination of several markers may be necessary to identify patients that may benefit from
checkpoint inhibitors. High costs and restricted access to these tests impede their validation and use in
clinical practice.
Besides that, TME, and especially CAF and TAM, were identified within a resistance mechanism
for immunotherapy and are increasingly regarded as new potential therapeutic targets. Currently,
no TME-targeted therapy is used or investigated in particular for HNSCC treatment, but TAM
inhibitors are currently being investigated, alone or in combination with standard therapies, in several
solid tumors.
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